期刊名称：LETTERS IN DRUG DESIGN & DISCOVERY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims & Scope
Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
Instructions to Authors
Instructions for Authors
Manuscripts should be submitted openly to one of the following Editors without prior invitation at the following addresses:
Submissions from North and South America:
Dr. John Frank Honek
Department of Chemistry
University of Waterloo
Waterloo, ON N2L 3G1
Canada
Tel: +1-519-888-4567 ext. 5817
E-mail: jhonek@uwaterloo.ca
Dr. John L. Neumeyer
Director, Medicinal Chemistry Laboratory
Alcohol and Drug Abuse Research Center
McLean Hospital, Harvard Medical School
115 Mill Street, Belmont, MA 02478
USA
Tel: 617-855-3388
Fax: 617-855-2519
E-mail: jneumeyer@mclean.harvard.edu
Submissions from Europe:
Dr. Sabbir Ahmed
Department of Pharmacy
School of Chemical and Pharmaceutical Sciences
Kingston University, Penrhyn Road
Kingston upon Thames, Surrey, KT1 2EE
UK
Tel. : +44 (0)20 8547 2000 ext. 62433
Fax. : +44 (0)20 8547 7562
E-mail : S.AHMED@KINGSTON.AC.UK
Submissions from Japan:
Dr. Yoshio Okada
Department of Medicinal Chemistry
Faculty of Pharmaceutical Sciences
Kobe Gakuin University
Nishi-ku, Kobe 651-2180
Japan
Tel: +81-78-974-1551
Fax: +81-78-974-5689
E-mail: okada@pharm.kobegakuin.ac.jp
Submissions from Asia:
Prof. Atta-ur-Rahman, FRS
H.E.J. Research Institute of Chemistry
University of Karachi, Karachi-75270
Pakistan
Tel: (+92)-21-482-4924, (+92)-21-482-4925
Fax:(+92)-21-461-2073, (+92)-21-497-7491, (+92)-21-497-5781, (+92)-21-481-9018, (+92)-21-481-9019
E-mail: mhej@cyber.net.pk
Letters Length: The published Letter, written in English, can be 2, 4, 6, 8 or 10 pages of the journal's format which can be reviewed at the website www.bentham.org/lddd with a word count per page of ca. 900 words.
Manuscript Organization: The manuscript should be divided as: Title page, abstract and the main text. The text may be subdivided further according to the areas to be discussed. The Acknowledgements (if any) and Reference sections must then follow. The first page should contain the title, the author's names (initials and surname only), with an asterisk in front of the name of the principal author.
Conflict of Interest: Financial contributions to the work being reported should be clearly acknowledged, as should any potential conflict of interest.
Abstract: The abstract should not exceed 50 words and it should condense the essential features of the letter article, with the focus on the major advances in the field.
Graphical Abstract: Authors must supply a graphical abstract when the paper is first submitted. The abstract should summarise the contents of the paper in a concise, pictorial form useful for rapid scanning of the journal. The manuscript title, authors and affiliations should be identical to those in the main paper. An example can be found in the journal following these instructions. Graphical abstracts must fit within the area shown in the example.
Key Words: Authors must supply up to six key words along with their manuscript.
Text: The main text should begin on a separate page and it may be subdivided into separate sections. The reference numbers should be given in square brackets in the text. Acknowledgements should be kept to a minimum.
Tables:
- Data Tables should be submitted in Microsoft Excel or in Microsoft Word table format.
- Each table should include a title/caption explaining what the table shows. Detailed legends may then follow.
- Tables should be given on separate pages with indications on the left hand margin to the text, as to the appropriate placement of the tables.
- Tables should not contain vertical rules.
- Columns and rows of data should be made visibly distinct by ensuring the borders of each cell display as black lines.
- Tables should be numbered consecutively in order of their citation in the body of the text, with Arabic numerals.
- If a reference is cited in both the table and text, insert a lettered footnote in the table to refer to the numbered reference in the text.
- Tabular data provided as additional files can be submitted as an Excel spreadsheet.
Figures / Illustrations:
All authors must strictly follow the guidelines below for preparing illustrations for publication in Letters in Drug Design & Discovery.
Editorial Requirements:
The quality of the illustrations printed in the journal largely depends on the quality of the figures/illustration provided by the author. In preparing artwork or graphics for publication, keep in mind the following points.
- Submit the original artwork or a photographic print of the original for publication.
- Do not submit photocopies. (Hardcopy submission requirement).
- Illustrations should be provided as separate files, not embedded in the text. (Hardcopy submission requirement).
- Remove all color from graphics except for those illustrations (Greyscale), which are to be printed in color.
- Good quality of hardcopy originals is a requirement.
- Figures should be referred to as 揊ig. (1)? 揊ig. (2)?etc. in the text with figure numbers in bold within round bracket.
- Revised manuscripts should contain a complete set of artwork and photographs.
Technical Details:
- Figures should be provided on high quality, white, smooth opaque paper. (Hardcopy requirement).
Format & Resolution:
- The following file formats can be accepted. (Preference in order of appearance): PDF, TIFF, JPEG, GIF.
- Illustrations must fit a single or double column format on the journal page, according to the following guideline below:
|
HEIGHT |
WIDTH |
|
SINGLE COLUMN |
24 cm (max) |
8.5 cm (max) |
|
DOUBLE COLUMN |
24 cm (max) |
18 cm (max) |
- Whenever possible, submit graphics that do not have to be reduced to fit the standard figure size.
- Use the best resolution available (hardcopy submission requirement). For online submission the maximum resolution is 300 dpi.
- Avoid textures and shadings giving a three-dimensional effect to the illustration.
- Symbols and lettering in the illustration should be of similar size.
- Smaller lettering is used.
- Font: Times New Roman or Helvetica is preferable. Font size: 10pt (maximum).
- Line drawings should have clear and sharp lines and should be of uniform density. Moreover, lines should be continuous without any breaks.
- Do not use lines thinner than 1 point.
- Required resolution for online submission is 300 dpi. In case of hardcopy submission, please use the maximum resolution available.
Color Figures / Illustrations:
Photographs:
Submit high-contrast prints that are of single- or double-column width so that they will not have to be reduced when printed. Negatives are not acceptable. However, in case of hardcopy submission, color illustrations and plates can be published from 35 mm color slides.
Chemical Structures: Chemical structures must be prepared according to the guidelines below.
Structures should be prepared using a suitable drawing program e.g. ChemDraw and provided as separate file, submitted both on disk and in printed formats.
Numbers in bold should identify all chemical structure. If a name is also used to describe the compound, the associated number if required should be in bold and parenthesis, e.g. 揷ompound (1)?
Structure Drawing Preferences:
[As according to the ACS style sheet]
Drawing Settings:
Chain angle 120?/P>
Bond spacing 18% of width
Fixed length 14.4 pt (0.500cm, 0.2in)
Bold width 2.0 pt (0.071cm, 0.0278in)
Line width 0.6 pt (0.021cm, 0.0084in)
Margin width 1.6 pt (0.096cm)
Harsh spacing 2.5 pt (0.088cm, 0.0347in)
Text Settings:
Font Times New Roman / Helvetica
Size 10pt
Under the Preference Choose:
Units points
Tolerances 3 pixels
Under Page Setup Use:
Paper US letter
Scale 100%
References: For the format of references, see the ACS Style Guide, pp 106-114,
Examples:
Journal Reference:
Barton, D.H.R.; Brewster, A.G.; Ley, S.V.; Rosenfield, M.N. J. Chem. Soc. Chem. Commun., 1977, 147, 2356.
Book Reference:
Rahman, A.-U.; Shah, Z. Stereoselective Synthesis in Organic Chemistry, Springer-Verlag: New York, 1993.
Book Chapter Reference:
Wheeler, D.M.S.; Wheeler, M.M. In Studies in Natural Products Chemistry; Atta-ur-Rahman, Ed.; Elsevier Science B. V: Amsterdam, 1994; Vol. 14, pp. 3-46.
Abstracts, unpublished data and personal communications (which can be only included if permission has been obtained) should not be given in the references section but they may be mentioned in the text and details provided as footnotes. All authors of referenced papers must be cited and there must be no use of the short hand version of et al. when citing authors. Abbreviations should be defined the first time that they are used in the manuscript and a list of abbreviations should be provided.
Manuscript Submission: Manuscripts may be submitted online or by conventional, hardcopy submission. Two copies of the manuscript must accompany the original along with the soft copy of the manuscript on a computer floppy disk(s) in MS Word file format (or created in any other well-known word processing software) should be submitted. To achieve rapid publication authors are encouraged to e-mail or fax their submission to the appropriate editorial office (see above) at the same time that they mail the manuscript. For even faster publication, authors are encouraged to submit their entire manuscript via Bentham抯
online submission service (see below). Authors must provide their full address, telephone and Fax numbers with E-Mail address with all submissions. For expedient and speedy reviewing of author's manuscripts, authors are strongly advised to include the PDF file of their manuscript on a floppy or zip disk, into the mailing material. At the same time the package is mailed, please also send by e-mail a copy of the PDF file of the manuscript to the editorial office.
Online Manuscript Submission: (preferable)
To facilitate speedy and cost-effective submission of manuscripts, an online submission and tracking service via Internet is being offered. We would prefer that you submit your full manuscript online via our online submission service available at www.bentham-mps.org or by FTP Submission at www.bentham-ftp.org
For online submission, please provide your complete manuscript in the form of a single zipped folder containing all the material (main text, figures/ illustrations, scanned photographs, tables, chemical structures drawn in ChemDraw) as separate files and a PDF version of the entire manuscript with all the figures/ illustrations / tables / chemical structures etc., embedded in the text exactly in the manner as they should appear in printing.
Authors are required to proofread the PDF version of their manuscript before submission. The article will be published exactly as received and the Publishers will not be responsible for any error occurring in the manuscript in this regard.
For online submission of manuscripts, these should be submitted via our online manuscript submission service available at www.bentham-mps.org or by FTP submission at www.bentham-ftp.org
You may, however, still submit your manuscripts through conventional surface mail.
Page Charges: No page charges will be levied to authors.
Language Editing: Manuscripts submitted containing many English typographical errors will not be published. Authors from non-English language countries are advised to use the services of our professional language editing department prior to submitting their manuscript to the Journal. Please contact Bentham Publishing Services www.bentham.org/bps for a language editing quote at e-mail: bps@bentham.org stating the total number of words of the article to be edited.
Proofs: Authors are sent page proofs. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 48 hours. Authors will be charged for excessive changes made at the page proof stage.
Reprints: Each first named author will receive by e-mail a free copy of their article as a PDF file. The PDF file is a watermarked version of the published article which is exclusively for the author's own use and may not be copied or distributed. Reprints may be ordered from the Publisher prior to publication of the article. First named authors may also order a personal print and online subscription of the journal at 50% off the normal subscription rate by contacting the subscription department at e-mail: subscriptions@bentham.org
Bentham Open Access: Accepted articles can be published online for an immediate free open access for all to view. Open access publishing provides the maximum dissemination of the article to the largest audience. Authors must pay for this service. For more information please contact us at e-mail: openaccess@bentham.org
Reviewing and Promptness of Publication: All papers submitted for publication will be immediately subjected to editorial scrutiny, usually in consultation with members of the Editorial Advisory Board. Every effort will be made to assess the papers quickly. The papers will be typeset and the proofs dispatched to the authors normally within 4 weeks of their acceptance.
Copyright: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication
Editorial Board
Editor in Chief:
Atta-ur-Rahman, FRS
HEJ Research Institute of Chemistry
University of Karachi
Karachi-75270
Pakistan
Associate Editors:
H. -Y. Koh (Korea Inst. of Science and Technology, Seoul, Korea)
Y. Kurogi (Cambridge Isotope Laboratories, Inc., Andover, MA, USA)
E.J. LaVoie (The State Univ. of New Jersey, New Jersey, USA)
K. Maiese (Wayne State University, Detroit, MI, USA)
A. Makriyannis (University of Connecticut Storrs, CT, USA)
J.J. Nestor, Jr. (Sequenom Pharmaceuticals, San Diego, CA, USA)
B. Wang (Georgia State University, Atlanta, GA, USA)
D.J. Waxman (Boston University, Boston, MA, USA)
Regional Editors:
S. Ahmed (Kingston University, Surrey, UK)
J.F. Honek (University of Waterloo, Ontario, Canada)
Y. Okada (Kobe Gauin University, Nishi-ku, Japan)
J.L. Neumeyer (McLean Hospital, Belmont, MA, USA)
Editorial Advisory Board:
S.S. Abdel-Meguid (Suntory Pharma. Res. Lab. LLC, Cambridge, MA, USA)
J.D. Adams, Jr. (Univ. of Southern California, Los Angeles, CA, USA)
J. Alvarez-Builla (G., Universidad de Alcal? Madrid, Spain)
O.A.C. Antunes (Instituto de Qu韒ica, Rio de Janeiro, Brazil )
M. Asanuma (Okayama Univ. Grad. Sch. Med. & Dent., Okayama, Japan)
J. Baranowska-Kortylewicz (University of Nebraska, NE, USA)
E.J. Barreiro (Universidade Federal do Rio de Janeiro, RJ, Brazil)
D.B. Berkowitz (University of Nebraska, Lincoln, NE, USA)
T. Burke (National Cancer Institute, Frederick, MD, USA)
F.P. Bymaster (Lilly Research Laboratories, Indianapolis, IN, USA)
E.V. Babaev (Moscow State University, Mascow, Russia)
F.C. Barone (GlaxoSmithKline, King of Prussia, PA, USA)
F.I. Carroll (Research Triangle Institute, NC, USA)
B.K. Cassels (Universidad de Chile, Santiago, Chile)
C.H. Chen (Duke University Medical Center, Durham, NC, USA)
P.A. Cole (Johns Hopkins University, Baltimore, MD, USA)
J.Conn (Merck Research Laboratories, West Point, PA, USA)
M. Crider (Southern Illinois University Edwardsville, Edwardsville, IL, USA)
X. Chen (AtheroGenics, Inc., Alpharetta, GA, USA)
D. Colomer (Unitat D'hematopatologia, Barcelona, Spain)
W.-M. Dai (The Hong Kong Univ. of Sci. and Tech., Hong Kong, China)
D.R. Davis (University of Utah, Salt Lake City, UT, USA)
E.B. Desouza (Archemix Corporation, Cambridge, NA, USA)
J.W. Ellingboe (Wyeth Research, Pearl River, NY, USA)
D.K. Ferris (NCI-Frederick Cancer Res. & Dev. Center, Frederick, MD, USA)
H.C. Fibiger (Eli Lilly and Company, Indianapolis, IN, USA)
A.J. Fischman (Massachusetts General Hospital, Boston, MA, USA)
D. Flynn (Neogenesis Pharmaceuticals Inc., Cambridge, MA, USA)
K.R. Fox (University of Southampton, Southampton, UK)
F.K. Friedman (National Cancer Institute, Bethesda, MD, USA)
E.P. Garvey (GlaxoSmithKline, Research Triangle Park, NC, USA)
M.A. Geyer (University of California San Diego, La Jolla, CA, USA)
D.S. Goodsell (The Scripps Research Institute, La Jolla, CA, USA)
S. Guccione (University of Catania, Catania, Italy)
E. Garattini (Instituto di Ricerche Farmacologiche, Milan, Italy)
S.P. Gupta (Birla Institute of Technology and Science, Pilani, India)
A. Harvey (University of Strathclyde, Glasgow, UK)
F.F. Hefti (Rinat Neuroscience Corporation, South San Francisco, CA, USA)
J.D.M. Herscheid (VU University Medical Center, Amsterdam, The Netherlands)
J. Haveman (University of Amsterdam, Amsterdam, The Netherlands)
H.N. Jayaram (Indiana University School of Medicine, Indianapolis, IN, USA)
A.Y. Jeng (Novartis Pharmaceuticals Corp., East Hanover, NJ, USA)
K.-T. Jeang (Molecular Virology Section, Bethesda, MD, USA)
M. Kahn (University of Washington, Seattle, WA, USA)
M. Kassiou (Royal Prince Alfred Hospital, Camperdown, Australia)
T.H. Koch (University of Colorado at Boulder, CO, USA)
H. Kubinyi (Donnersbergstrasse 9, Weisenheim am Sand, Germany)
A.V. Kalueff (National Institute of Mental Health, Bethesda, MD, USA)
A. Kamal (Indian Institute of Chemical Technology, Hyderabad, India)
H.J. Koch (Psychiatrische Universitatklinik, Regensburg, Germany)
P.Y. Lam (Bristol-Myers Squibb Co., Princeton, NJ, USA)
J. Lee (Seoul National University, Seoul, Korea)
H. LeVine (Pfizer Global Research & Development, Ann Arbor, MI, USA)
A.J. Lewis (Signal Res. Division of Celgene, San Diego, CA, USA)
B.T. Liang (University of Connecticut Health Center, Farmington, CT, USA)
G.K. Lloyd (Nereus Pharmaceuticals Inc, San Diego, CA, USA)
T. Loftsson (University of Iceland, Reykjavik, Iceland)
S. Lang (Technical Services & Operational Excellence, Costa Mesa, CA , USA)
W. Le (Baylor College of Medicine, Houston, TX, USA)
J.T.M. Linders (Johnson & Johnson Pharm. Res. & Develop., Beerse, Belgium)
R. Mairs (University of Glasgow, Glasgow, UK)
J.E. Manson (Brigham and Women's Hospital, Boston, MA, USA)
B.E. Maryanoff (Johnson & Johnson Pharmaceuticals. Res. & Dev., PA, USA)
R. P. Mason (Univ. Texas Southwestern Medical Ctr., Dallas, TX, USA)
S. Mehta (Matinal Circle, San Diego, CA, USA)
S. Mobashery (University of Notre Dame, Notre Dame, IN, USA)
C.B. Marsh (Ohio State University, Columbus, OH, USA)
G. Mccleane (Rampark Pain Center, Lurgan, Ireland)
P.A. Newhouse (University of Vermont, Burlington, VT, USA)
A.H. Newman (National Institutes of Health, Baltimore, MD, USA)
F.G. Njoroge (Schering-Plough Research Institute, Kenilworth, NJ, USA)
D.A. Nugiel (Bristol-Myers Squibb, Wilmington, DE, USA)
G. Naray-Szabo (E鰐v鰏 Lor醤d University, Pazmany Hungary)
I. Ojima (State University of New York, Stony Brook, NY, USA)
D.F. Ortwine (Pfizer Global Res. & Dev., Ann Arbor, MI, USA)
J. Pearlman (Dartmouth Medical School, NH, USA)
L.M. Pelus (Indiana University, Indianapolis, IN, USA)
G. Perry (University of Texas, San Antonio, Texas, USA)
E. Pop (Alchem Laboratories Corporation, FL, USA)
M. Pascu (Biomedicine and Molecular BioSciences, Brussels, Belgium)
J.E. Rice (Rutgers University, Piscataway, NJ, USA)
K.C. Rice (National Institute of Health, Bethesda, MD, USA)
P.D. Roepe (Georgetown University, Washington, DC, USA)
A W. Root (Univ. of South Florida, St. Petersburg, FL, USA)
D.P. Rotella (Bristol-Myers Squibb, Princeton, NJ, USA)
T.K. Sawyer (ARIAD Pharmaceuticals, Cambridge, MA, USA)
R.B. Silverman (Northwestern University, Evanston, IL, USA)
N.E. Sladek (University of Minnesota, Minneapolis, MN, USA)
D.S. Soriano (University of Pittsburgh-Bradford, Bradford, PA, USA)
R. Sabatowski (University of Cologne, Koln, Germany)
D. Stahl (Institute for Transfusion Medicine, Munster, Germany)
R.E. Tanzi (Massachusetts General Hospital, Charlestown, MA, USA)
A. Toninello (Universit?degli Studi di Padova, Padova, Italy)
G.P. Tuszynski (Temple University, Phila, PA, USA)
H.F. VanBrocklin (Lawrence Berkeley National Lab., Berkeley, CA, USA)
C.D. Wegner (Pfizer Global R&D, St. Louis, MO, USA)
R.L. White (Dalhousie University, Nova Scotia, Canada)
J.S. Williamson (University of Mississippi, MS, USA)
L. Yang (Merck Res. Lab., Rahway, NJ, USA)
Z.-J. Yao (Shanghai Institute of Organic Chemistry, Shangai, China)
R. Zhang (University of Alabama, Birmingham, AL, USA)
|
刊名字顺( Alphabetical List of Journals):
返回页首 